AOD-9604 vs Orforglipron
A side-by-side research comparison of AOD-9604 and Orforglipron across mechanism, dosing, half-life, benefits, side effects and research status.
Comparison table
| Attribute | AOD-9604 | Orforglipron |
|---|---|---|
| Full name | Advanced Obesity Drug Fragment 176-191 (Modified) | Orforglipron (Oral Non-Peptide GLP-1 Agonist) |
| Category | Weight Management | Weight Management |
| Status | Research compound | Phase 3 Clinical Trial |
| Mechanism | Mimics the lipolytic domain of growth hormone (hGH 176-191), stimulating fat oxidation and inhibiting de novo lipogenesis through pathways independent of IGF-1 and growth signaling. | Small molecule agonist of GLP-1 receptors that mimics native GLP-1 binding without requiring peptide structure. Achieves full receptor activation with standard oral bioavailability. |
| Molecular weight | 1815.08 Da | ~550 Da |
| Half-life | ~2-3 hours | 25-60 hours |
| Bioavailability | ~90% subcutaneous | Moderate-High (oral) |
| Typical dose | 300 mcg | 12-45 mg |
| Frequency | Daily (morning, fasted) | Once daily |
| Route | Subcutaneous injection | Oral |
AOD-9604 reported benefits
- Fat loss without muscle wasting
- No effect on blood sugar
- Cartilage repair properties
- No HGH-related side effects
Orforglipron reported benefits
- Oral administration (no injection)
- No fasting requirement
- Significant weight loss (8-14%)
- Small molecule stability
- Lower manufacturing cost potential
Related comparisons
Research and educational reference only. Not medical advice.